In view of failure to detect EpCAM negative “uncapturable” and CK negative “invisible” CTCs due to inevitable drawbacks of current EpCAM/CK-dependent methodologies, an integrated tumor cell surface molecule-independent SE-iFISH® platform has been systematically developed and clinically validated (Fig. 4) [7, 9, 31]. This evidence concerns the gene EPCAM and neoplasm.